Publications by authors named "Jody Bozek"
Introduction: Released sympathetic neurotransmitter norepinephrine (NE) in the heart is cleared by neuronal uptake-1 and extraneuronal uptake-2 transporters. Cardiac uptake-1 and -2 expression varies among species, but the uptake-1 is the primary transporter in humans. LMI1195 is an NE analog labeled with (18)F for PET evaluation of cardiac neuronal function.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the relationship between regional cardiac sympathetic denervation (RCSD) and noradrenaline transporter (NAT) function, using a new PET imaging agent called LMI1195.
- LMI1195 was tested for its ability to detect RCSD in a rabbit model and was compared to other substances, showing significant potential for imaging.
- The findings indicate that RCSD not only can be imaged effectively with LMI1195 but also contributes to increased cardiac risks when treated with the antiarrhythmic drug dofetilide.
Article Synopsis
- Heart failure can affect cardiac sympathetic nerve function, and LMI1195 is a new PET imaging agent that targets the norepinephrine transporter (NET) to help identify individuals at risk for serious cardiac issues.* -
- When tested, LMI1195 showed comparable binding affinity and uptake kinetics to norepinephrine and 123I-MIBG, indicating similar effectiveness in tracking NET in cardiac tissue.* -
- LMI1195 demonstrated significantly higher heart-to-liver and heart-to-lung uptake ratios in animal studies, suggesting improved imaging clarity and potential for better assessment of cardiac health compared to traditional methods.*
Background: BMS747158 labeled with (18)F is being developed for PET myocardial perfusion imaging. Imaging studies showed clear detection of necrotic tissue in acute myocardial infarcted (MI) animals and a good safety profile in normal animals. This study evaluated BMS747158 imaging and cardiovascular safety in a rabbit model of chronic MI with cardiac compromise.
View Article and Find Full Text PDFBackground: BMS747158-02 is an (18)F-labeled agent being developed for PET myocardial perfusion imaging. This study examined impacts of feeding state and anesthetic on cardiac imaging and uptake of this agent in rats in comparison with (18)F-fluorodeoxyglucose (FDG).
Methods And Results: Studies were performed in rats either nonfasted or food deprived for 20 hours and anesthetized with either sodium pentobarbital (Pentob) or ketamine and xylazine (Ket/Xyl).
Purpose: Myocardial extractions of mitochondria complex I (MC-I) inhibitors were high and well correlated with flow. This study assessed the potential of MC-I inhibitors to be developed as myocardial perfusion imaging (MPI) agents.
Methods: RP1003, RP1004, and RP1005 representing three classes of MC-I inhibitor were synthesized and radio-labeled with (18)F.
Background: BMS-747158-02 is a novel fluorine 18-labeled pyridazinone derivative designed for cardiac imaging. The uptake and retention mechanisms of F-18 BMS-747158-02 in cardiac myocytes were studied in vitro, and the biodistribution of F-18 BMS-747158-02 was studied in vivo in mice.
Methods And Results: Fluorine 19 BMS-747158-01 inhibited mitochondrial complex I (MC-I) in bovine heart submitochondrial particles with an IC(50) of 16.